US 12,390,541 B2
Mutant variants of PD-1 receptor with selective binding to PD-L1 and uses thereof
Andras Fiser, New York, NY (US); Rojan Shrestha, Bronx, NY (US); Steven C. Almo, Pelham, NY (US); and Sarah C. Garrett, Bronx, NY (US)
Assigned to Albert Einstein College of Medicine, Bronx, NY (US)
Appl. No. 17/278,869
Filed by Albert Einstein College of Medicine, Bronx, NY (US)
PCT Filed Sep. 18, 2019, PCT No. PCT/US2019/051640
§ 371(c)(1), (2) Date Mar. 23, 2021,
PCT Pub. No. WO2020/068500, PCT Pub. Date Apr. 2, 2020.
Claims priority of provisional application 62/736,477, filed on Sep. 26, 2018.
Prior Publication US 2022/0047729 A1, Feb. 17, 2022
Int. Cl. A61K 51/08 (2006.01); C07K 14/705 (2006.01)
CPC A61K 51/08 (2013.01) [C07K 14/70532 (2013.01); C07K 2319/30 (2013.01)] 12 Claims
 
1. A human Programmed Cell Death-1 (PD-1) receptor mutant comprising at least the first 149 consecutive amino acids of SEQ ID NO:1 with mutation Y68R or Y68K, wherein the mutant has selectivity for PD-LI compared to PD-L2 and wherein the mutant has undetectable PD-L2 binding.